

CURZA RECEIVES \$300K ACS GRANT

Titled "Repurposing Old Scaffolds as New Anti-Tubercular Leads"

SALT LAKE CITY, Utah—September 2016—Curza is proud to announce that they've received the Teva Pharmaceuticals Marc A. Goshko Memorial Grant, a philanthropic grant program that supports academic researchers in the fields of organic and medicinal chemistry, for their project titled, "Repurposing Old Scaffolds as New Anti-Tubercular Leads." Administered by the American Chemical Society Office of Research Grants, the funding is provided by Teva Pharmaceuticals. This grant awards \$100,000 per year for 3 years.

Though tuberculosis remains one of the world's deadliest diseases and resistance to current treatments continues to rise, no new tuberculosis treatment has been developed in nearly 20 years. These funds will be used to further develop Curza's lead program (CZ-02) and explore its potential to shorten tuberculosis treatment regimens. CZ-02 is a new class of broad spectrum antibiotics, focused on treating medical areas of unmet need, such as drug-resistant Gram-negative bacteria, tuberculosis, and ESKAPE pathogens.

About Curza— Curza is a Utah-based drug development company focused on developing novel therapeutics to combat antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and is backed by Clarke Capital Partners and other private investors. Visit www.curza.com for more information.

About ACS—The American Chemical Society (ACS) advances the broader chemistry enterprise and its practitioners' scientific research through peer reviewed journals, research, conferences, grants, awards, and educational resources. Visit www.acs.org for more information.

For media inquiries, please contact: Ryan Davies at rd@curza.com